Objective: Given conflicting data and current guidelines, low-dose corticosteroids are often used in the treatment of septic shock. To evaluate the therapeutic benefit of early low-dose corticosteroid in patients with septic shock. Design: Retrospective, multicenter, propensity-matched cohort study. Setting: ICUs of 28 academic and community hospitals in three countries between 1996 and 2007. Subjects: Six thousand six hundred sixty-three eligible patients with septic shock of whom 1,838 received IV low-dose corticosteroid treatment within 48 hours of the diagnosis of septic shock and were matched to a comparable group who did not receive low-dose corticosteroid. Measurements and Main Results: The primary outcome was 30-day mortality. Mortality analyses were stratified by severity of illness (Acute Physiology and Chronic Health Evaluation II quartile). Using a Cox proportional hazards model, corticosteroid therapy was associated with similar 30-day mortality when compared with the matched control cohort (652/ Conclusion: Early administration of low-dose corticosteroid is not associated with decreased mortality when it is administered to unselected patients with septic shock. A beneficial effect of low-dose corticosteroid on mortality may exist in patients with the highest severity of illness. Future trials of low-dose corticosteroid
; the Cooperative Antimicrobial Therapy of Septic Shock Database Research Group T he use of steroids for patients with septic shock has undergone several major shifts over the past few decades. In one of the first randomized studies of corticosteroid therapy for septic shock, Schumer (1) found decreased mortality in patients who received supraphysiologic (immunomodulatory-immunosuppressive) doses of methylprednisolone (30 mg/kg). This study led to the widespread use of high-dose corticosteroids for septic shock in the 1970s and 1980s as the concept of sepsis as an uncontrolled inflammatory response became popular. Subsequently, large randomized studies in the late 1980s and early 1990s failed to demonstrate benefit and even suggested harm (2) (3) (4) (5) (6) . After these studies, the routine use of high-dose corticosteroids in septic shock was largely abandoned.
The use of corticosteroids for septic shock management enjoyed a rebirth early in the last decade with the publication of several studies suggesting accelerated vasopressor liberation and reduced mortality associated with the use of low-(physiologic)-dose (200-300 mg/d hydrocortisone) corticosteroids (LDS) in a subset of patients with septic shock (7) (8) (9) . The basis of this benefit was postulated to be the presence of "relative" adrenal insufficiency in this condition (10, 11) . The efficacy of LDSs in septic shock was questioned after the publication of the Corticosteroid Therapy of Septic Shock (CORTICUS) trial (12) and supportive meta-analyses (13) . As a consequence, the role of corticosteroids in the treatment of septic shock remains a question (10) .
The Surviving Sepsis Campaign currently recommends consideration of the use of corticosteroids for patients with septic shock who have responded poorly to fluid resuscitation and vasopressor agents (14) . Given the clinical equipoise on the role of LDS in septic shock, we performed a propensity-matched study examining the impact of the use of LDSs on survival in septic shock using a multinational septic shock database.
METHODS
We undertook a retrospective review of adult (≥ 18 yr) patients diagnosed with septic shock. The Health Ethics Board of the University of Manitoba and each individual participating center approved a waived consent protocol. Between 1996 and 2007, consecutive adult patients with septic shock from 28 medical institutions in Canada, the United States, and Saudi Arabia were retrospectively identified using either internal ICU registries/databases or International Classification of Diseases (ICD-9 or 10) coding strategies.
Data collection methods have been previously described (15) (16) (17) (18) . Data were collected by trained research nurses/medical students using a standardized and piloted data extraction template. Each institution contributed a minimum of 50 cases. Each potential case was screened to determine if the case met specific criteria for septic shock as described by the 1991 Society of Critical Care Medicine/American College of Chest Physicians Consensus Statement on Sepsis Definitions (19) . The process used to identify the final study population is outlined in Figure 1 .
Clinical infection definitions were adapted from previous recommendations or studies (17, 20, 21) . In order to qualify as potential pathogens causing shock, isolates from anatomic sites and/or blood cultures were required to have been obtained within 48 hours of onset of shock. A priori criteria were developed to determine the primary pathogen/pathogens and to assess the appropriateness of antimicrobial therapy across participating institutions (16, 17) . Questionable cases or data elements were reviewed and adjudicated by the principal investigator.
A primary admission diagnosis of septic shock was confirmed in 8,670 patients. A priori exclusion criteria included death within the first 48 hours of ICU admission, failure to initiate appropriate antimicrobial therapy or implement indicated source control, and chronic steroid dependence (> 20 mg daily prednisone equivalent). Data on the use of LDS was obtained from each medical chart. To capture only the effect of early LDS therapy, patients who received LDS more than 48 hours after documentation of shock were excluded. Similarly, those who received highdose steroid therapy (> 80 mg prednisone equivalent/d) were excluded from the analysis (Fig. 1 ). All patients included in the LDS group had received at least one dose of corticosteroid within the 48-hour window (with an order to continue LDS treatment). Neither the duration of LDS therapy nor the adrenocorticotropic hormone (ACTH) response was recorded. 
Study Variables
Variables collected included patient demographics, baseline comorbidities, Acute Physiology and Chronic Health Evaluation (APACHE) II score (22) at shock onset, physiologic/laboratory measures, the use of hemodynamic or ventilatory support, and the administration of IV LDS therapy. The first use of appropriate antimicrobial therapy was determined for all cases. Appropriate antimicrobial therapy was defined as an antibiotic with in vitro activity appropriate to isolated pathogenic organisms or, if an organism was not isolated, appropriate for the underlying clinical syndrome (16) . The presumed or documented site of infection causing septic shock, microbiological culture results, and the time to initial appropriate antimicrobial therapy from the onset of hypotension were also recorded. Combination antibiotic therapy was defined as concomitant use of two or more appropriate, IV, bactericidal antibiotics with different mechanisms of action for at least 24 hours after the onset of hypotension (18) .
Outcome Measures
The primary outcome variable was mortality over 30 days in relation to early LDS therapy. Mortality stratified by severity of illness (APACHE II quartile) was preidentified as a secondary outcome measure. Other a priori secondary endpoints included ICU and hospital mortality, ICU and hospital length of stay, and the number of ventilator-and vasopressor inotrope-free days in the first 30 days.
Statistical Analysis
Baseline characteristics of control and LDS therapy groups were compared using Student t test or the Wilcoxon rank-sum test for continuous variables and the chi-square test for categorical variables. All reported p values were two-tailed. Because LDS therapy was not randomly assigned, a propensity analysis was undertaken to account for potential confounding factors and selection biases. The propensity-matching and analytic methods used in this study incorporated aspects from several reference sources (23, 24) and have been used in several of our previous publications (15, 18, 25) . A propensity score for LDS therapy use was developed using multivariable logistic regression. This score represents the probability that a patient would receive LDS therapy based on variables, which were known or suspected to influence group assignment or to affect mortality risk. Variables included in the derivation of the propensity score are shown in Supplemental Table 1 (Supplemental Digital Content 1, http://links.lww.com/CCM/B12). Among these were age, sex, APACHE II score, the number of day 1 organ failures, occurrence of shock before initiation or during therapy with an appropriate antibiotic, appropriateness of initial antimicrobial therapy, time to the initial dose of the first appropriate antibiotic (following documentation of sepsis-associated hypotension), site of infection acquisition (community, nosocomial), preexisting medical conditions, infecting organism, presence of bacteremia, primary antibiotic therapy, anatomic site of infection, volume of fluid resuscitation in the first hour of hypotension, use of therapies including source control, combination antibiotics, activated protein C, mechanical ventilation, and a variety of laboratory data at the time of shock diagnosis including WBC count, platelet count, the international normalized ratio, serum lactate, serum creatinine, and serum bicarbonate. The specific initial antimicrobial therapy used was also in the derivation.
To account for temporal and geographic practice variability, the date of ICU admission and hospital sites (region/academic vs nonacademic) was also incorporated as matching variables. Propensity scores were used to match patients who received LDS to a control patient using a Statistical Analysis Software (SAS) macro. A greedy matching procedure selected match pairs initially identical to five decimal places of probability (26) . If no match existed at five decimal places, matching would occur at four decimal places and so on. If no match existed at one decimal place, then that patient receiving LDS was excluded from the study.
Mortality over 30 days was assessed using a Cox proportional hazard model. Hazard models incorporated survival data over the complete duration of the study period (28 d) or until the time of censoring (i.e., discharge). Mortality estimates stratified by severity of illness (APACHE II quartiles) were assessed by the addition of an interaction term to the hazard model and time to initial appropriate antimicrobial therapy (27) . A hazard less than 1 signifies decreased risk of mortality in the LDS group compared with the control group. Statistical analyses were conducted using SAS version 9.1 (SAS Institute, Cary, NC). The confidence limits and p values reported reflect an α level of 0.05.
RESULTS

Baseline Characteristics
A total of 6,663 patients with septic shock could have potentially received LDS therapy within 48 hours of the onset of septic shock. LDS was administered to 2,031 of these patients (30.5%). Baseline demographics, preexisting medical conditions, and relevant clinical, physiologic, and laboratory data in the unmatched study population are summarized in Supplemental Table 1 (Supplemental Digital Content 1, http://links.lww.com/CCM/B12).
Several clinical differences between the LDS and control groups existed in the unmatched cohort. The mean admission APACHE II score in the LDS group was significantly higher than that in the control group as was the median number of organ failures on the day of presentation. The mean age in the LDS group was significantly lower. The median time to appropriate antimicrobial therapy and mean resuscitation fluid volume infused within the first 6 hours were similar in each group.
Although there were no differences noted in the unmatched prevalence of primary infection site culture-positive and blood-culture-positive infections, there were significant differences in the distribution of anatomic sites of infection and in causal pathogens. In particular, pneumonia was a more common cause of septic shock in the LDS group, whereas intraabdominal infections were more common in the control group. Perhaps as a consequence, Gram-negative infections were more common in control patients, whereas Gram-positive infections were more common in those who received LDS therapy.
LDS patients received 150-300 mg total daily dose of IV hydrocortisone in 94.8% of cases. Dexamethasone was used in 3.6% and methylprednisolone in 1.4% of the total. Fludrocortisone was used in only three cases. Baseline Characteristics Following Propensity Matching Using propensity scores, 1,838 of 2,031 of patients (91%) who received LDS were able to be matched. The c statistic for the propensity derivation model was 0.74. The range of propensity scores was identical in both the LDS and the control groups (LDS, 0.04-0.87; control, 0.04-0.87). The sd of the propensity scores was 0.18. The matching process eliminated all significant differences that existed between the LDS and control groups regarding patient demographics, preexisting medical conditions, and relevant clinical, physiologic, and laboratory variables (Supplemental Table 1 Fig. 2A) . Likewise, ICU and hospital mortality were similar in the LDS and control groups ( Table 2 ). There were no significant differences in the distribution of causes of death in each group (Table 2) .
In contrast, in the propensity-matched Cox model restricted to the highest APACHE II quartile, the risk of mortality over 30 days was lower in the LDS group compared with the control group (Fig. 3A) . The absolute reduction in 30-day mortality in patients in the highest APACHE II quartile was 5.2% (95% CI, 3-23%), with a corresponding hazard ratio of 0.81 (95% CI; 0.68-0.97; p = 0.02) ( Table 1) . Stratified analyses revealed a trend toward reduced mortality over 30 days with increased severity of illness (test for interaction p = 0.006) ( Table 1) . Similarly, the Table 2) . A parallel trend existed for ICU mortality (Table 2) . Modest increases in ICU, 30-day, and hospital mortality with the use of LDS in the lowest APACHE II quartiles did not achieve significance (Tables 1 and 2 ). Analysis of morality in the lowest half of severity of illness did not yield any change in the basic results, with p values of 0.14 and 0.12 for 30-day and hospital mortality, respectively, favoring harm with LDS therapy. In the subgroup of patients who received appropriate antimicrobial therapy most rapidly (≤ 1.75 hr from hypotension onset), there was a trend toward decreased (p = 0.09) mortality associated with LDS, with a test for interaction of p = 0.07 across the time quartiles.
Secondary Support Measures
The proportion of patients successfully liberated from mechanical ventilation and from vasopressor/inotrope support was similar in the LDS and control groups ( Table 3) . There were no differences in hospital or ICU length of stay among either the entire cohort (not shown) or among survivors (Table 3 ). In addition, ventilator and vasopressor/inotrope-free days were similar in both groups at 30 days (Table 3) . Log-rank analysis demonstrated no significant benefit to LDS therapy with respect to duration of vasopressor/inotrope dependence over 30 days (Fig. 2B ). An analysis restricted to the highest quartile of APACHE scores similarly failed to yield evidence of significant benefit over either 14 (Fig. 3B) or 30 days.
DISCUSSION
In this retrospective propensity-matched cohort study of patients with septic shock, we found that the use of corticosteroids was not associated with a reduction in 30-day or in-hospital mortality. These findings are in keeping with the recent CORTICUS trial that also found no reduction in mortality with the use of LDS. We found, however, a survival benefit (30 d and hospital mortality) limited to patients in the highest APACHE II quartile (≥ 30). In contrast to several other studies (7-9, 28, 29) , we did not demonstrate a shorter time to reversal of the shock state (as defined by liberation from vasopressor therapy).
The most severely ill patients disproportionately benefit from some therapies of sepsis. Our analyses of combination antimicrobial and heparin therapy have similarly shown maximal benefits in the most severely ill subset of patients with sepsis and septic shock (18, 25, 30) . Further, a meta-analysis/meta-regression analysis of human studies of CORTICUS indicated increasing probability of benefit with increasing severity of septic shock (31) . A recent study of canine staphylococcal pneumonia with septic shock also demonstrated that the benefit of LDS in terms of survival, shock reversal, and interleukin-6 generation is restricted to the most severely ill animals made septic with the highest dose of infused organisms (32) .
The potential mechanism of survival benefit for the most severely ill patients with septic shock is uncertain. Early studies using large, supraphysiologic doses (15-30 mg/ kg prednisone equivalent) were thought to act through an immunomodulatory mechanism potentially involving suppression of inflammatory cytokine production (3, 6) . However, the doses used in this analysis are more consistent with the doses used in more recent studies of low, "replacement" dose corticosteroid therapy (7, 12) . These doses have been associated with earlier resolution of shock (8, 9, 29) . Although a modestly shorter duration of vasopressor use in the highest quartile APACHE II LDS therapy group was noted in 15-day follow-up, this did not approach significance. This lack of a significant advantage in terms of pressor liberation in the most severely ill quartile receiving steroid therapy may be a consequence of a lack of resolution in our data collection. It is possible that had we been able to examine vasopressor duration in hourly rather than daily increments, a greater significance to the divergence may have been generated. The finding that a trend to increased harm exists in the least severely ill patients is also notable. Although this trend does not reach significance, it is supported by a significant test for interaction suggesting that the effects of LDS changes with variations in initial illness severity. These data strongly suggest that future randomized studies of LDS therapy of septic shock should be focused on patients with a high severity of illness. Investigators should also be cognizant of the possibility of harm associated with LDS therapy in those with low severity of illness.
Another interesting observation in our study pertains to the strong trend toward a greater potential benefit of LDS therapy in those receiving the most rapid appropriate antimicrobial therapy. Although speculative, this may pertain to the possibility of more rapid elimination of the pathogen burden with earlier therapy. The residual inflammatory (rather than infectious) injury may be more amenable to immunomodulation with LDS (33) . This possibility is supported by animal studies that demonstrate a higher frequency of persistent bacteremia in sepsis treated with LDS (32) .
There are significant strengths to this study. This analysis represents one of the single largest datasets on the impact of use of low-dose steroids in septic shock. This allows some important subset (sensitivity) analyses particularly by stratification of initial APACHE II score. In addition, the propensity-matching approach appeared to appropriately match discordant risk factors in the unmatched study populations. For example, the higher rate of chronic obstructive pulmonary disease, malignancy, and immunosuppression among those treated with LDS in the unmatched cohorts (possibly due to preexisting steroid therapy below the exclusion threshold in these patients) is completely reconciled with propensity matching (Supplemental Table 1 , Supplemental Digital Content 1, http:// links.lww.com/CCM/B12).
There are two major randomized controlled studies of LDS in sepsis (7, 12) . In the study by Annane et al (7), patients were randomized only if they had a documented systolic blood pressure of less than 90 mm Hg for at least 1 hour despite adequate fluid resuscitation with the use of vasopressors, lactate more than 2 mmol/L, decreased urine output, and need for mechanical ventilation. The inclusion criteria for CORTICUS were more liberal and patients were not as ill (12) . The severity of illness of our subjects fall in between that of the subjects of these two major trials and likely represent a more "real world" experience with the use of LDSs (34) .
There are several limitations to our study. Our study is a retrospective analysis. For that reason, the study results should be considered hypothesis generating only. In retrospective studies, unmeasured confounding variables may be present and cannot be accounted for in a multivariable logistic regression model or propensity-matched analysis. Although propensity matching mimics aspects of a randomized, controlled trial, all the major limitations of retrospective analysis still exist. In particular, in any retrospective treatment study, there is the potential for survival/immortal time bias (10, 35) . A patient who received LDS within a given timeframe would necessarily have to have survived to that time point, whereas someone who did not receive LDS at all, he or she may or may not have lived that long. In this study, all LDS group subjects had to have received the therapy within 48 hours of shock documentation. In order to address immortal time/survival bias and ensure that subjects not receiving LDS has an equivalent opportunity received it compared with the LDS group, death within 48 hours was identified a priori as an exclusion criterion. Although several other approaches to addressing immortal time/survival bias exist, each has its own limitations. Our approach has the advantage of simplicity and has been used in several of our previous studies (15, 18, 25) . However, this effort to resolve the immortal time/survival bias does necessarily exclude a significant portion of very sick patients who died within 48 hours. We are unable to comment about the potential utility of LDS therapy in this group.
Another specific limitation is that our database contains incomplete data with regard to steroid use. Only the specific corticosteroid used and the dose were recorded. The total duration of therapy is not available. Further, our LDS study subjects almost uniformly received hydrocortisone (95%) or, on occasion, dexamethasone or methylprednisolone (5% total). Only three patients received fludrocortisone which was the primary mineralocorticoid used in some trials (7) . In addition, we have no data regarding how many patients received an ACTH stimulation test and how many were responders or nonresponders. This factor is likely not important as the ACTH stimulation test is no longer recommended for this patient population (14, 36) . Finally, our dataset does not allow us to determine if patients who received steroids had higher rates of superinfection or recrudescence of their septic shock.
In conclusion, the use of LDS in patients with septic shock did not reduce 30-day or in-hospital mortality. In the most severely ill subgroup of patients with an APACHE II score more than or equal to 30, the use of LDS was associated with a significant decrease in 30-day and hospital mortality. Future studies of LDS therapy in septic shock may be more likely to yield evidence of benefit if they are focused on this cohort of patients. 
